Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: no drug Clear all
Completed Not applicable Interventional Accepts healthy volunteers

DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients

NCT02116179
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Hepatitis C
Interventions
DVD Intervention
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 49 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 16, 2026, 3:54 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

NCT01990196
View directory record Official record
Conditions
Prostate Cancer
Interventions
degarelix, enzalutamide, trametinib, dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 16, 2026, 3:54 AM EDT
Active, not recruiting Phase 2 Interventional

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

NCT04476953
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Fisetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Not applicable Interventional

Interactive Care Coordination and Navigation:RCT To Assess the Impact of a mHealth Intervention for Homeless Individuals

NCT05365867
View directory record Official record
Conditions
Number of Emergency Department and Hospital Visits Among Adults Experiencing Homelessness, Medication Adherence, Social Support, Pyschological Distress, Attainment of Social Needs (i.e., Housing, Employment, Receipt of Benefits)
Interventions
iCAN Group
Behavioral
Lead sponsor
Leticia R. Moczygemba
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 16, 2026, 3:54 AM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Early Phase 1 Interventional

AvenovaTM as a Sterile Skin Preparation Agent

NCT02990013
View directory record Official record
Conditions
Cleaning Product Causing Toxic Effect
Interventions
Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Not applicable Interventional Results available

Web Based Tools to Improve Medication Continuity in Adolescents With ADHD

NCT04386096
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Adherence, Medication
Interventions
Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software with no medication continuity tools
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

NCT04426695
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 16, 2026, 3:54 AM EDT
Withdrawn Phase 3 Interventional

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

NCT03508739
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
Interventions
Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Not applicable Interventional Results available

Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease

NCT03658811
View directory record Official record
Conditions
Dry Eye
Interventions
intense pulsed light
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 16, 2026, 3:54 AM EDT
Recruiting Phase 2 Interventional

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

NCT04105270
View directory record Official record
Conditions
Adenocarcinoma of Lung, Lung Cancer
Interventions
Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo
Drug · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 16, 2026, 3:54 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cannabis Consumption and Driving Impairment Assessment on a Closed Course

NCT06059677
View directory record Official record
Conditions
Cannabis Smoking, Driving Impaired
Interventions
Active smoked cannabis, Placebo smoked cannabis
Drug
Lead sponsor
Bayliss J. Camp, PhD
Government
Eligibility
21 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

NCT01558661
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
AG-013736 (AXITINIB)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 16, 2026, 3:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 16, 2026, 3:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Texas Family Health Patterns: A Study Across Generations

NCT02438254
View directory record Official record
Conditions
Alcohol and Other Drug Use Disorders
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 30 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Telephone Counseling for Tobacco Cessation

NCT01489579
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Telephone Counseling for Tobacco Cessation, Usual Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
View directory record Official record
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043
View directory record Official record
Conditions
Supportive, Ill-defined Sites
Interventions
paclitaxel, docetaxel, taxane, taxane
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Improving Flexibility With a Mindbody Approach

NCT01066325
View directory record Official record
Conditions
General Low Back Hip and Hamstring Flexibility
Interventions
Neuro Emotional Technique, Stretching Instruction
Behavioral · Other
Lead sponsor
Parker Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 16, 2026, 3:54 AM EDT
Terminated Phase 2 Interventional

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

NCT02997189
View directory record Official record
Conditions
Cisplatin Induced Hearing Loss
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 16, 2026, 3:54 AM EDT
Completed Not applicable Interventional

Primary Care Clinician Commitments to Choosing Wisely®

NCT02247050
View directory record Official record
Conditions
Health Services Misuse, Physician's Practice Patterns, Guideline Adherence, Unnecessary Procedures, Health Care Costs
Interventions
Commitment invitation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 16, 2026, 3:54 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

NCT05288023
View directory record Official record
Conditions
Resistance Bacterial, Morality, Child Health, Implementation
Interventions
Azithromycin for Oral Suspension
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month and older
Enrollment
169,707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 16, 2026, 3:54 AM EDT